BW,
I haven't been posting as much simply because my position is set and I'm waiting for the ponatinib trial to start, the rida final analysis, and an update on the endometrial trial.
fwiw, I like the ponatinib trial design. Since it's so unique, I would think the FDA had input. imho, it sure seems like the T315I mutation arm was structured in such a way as to allow the for quick approval if the results warrant while allowing the remaining patient groups to continue in the trial.
News 
Market Data 
Discover 
